(also known as Persantin
) is a drug in use for the past 55 years for treating angina (a cardiovascular condition). It has a well established safety profile. The typical daily oral dose is between 200mg and 400mg.
In 2012 a breakthrough was reached when dipyridamole in eye drop form was discovered to have excellent effects in treating dry eye, pterygium, pinguecula, cataract, nevus, viral eye infection, MGD
and a variety of other eye disorders.
The dipyridamole eye drops are prepared by specialist pharmacies, where each drop contains 1/50,000th of the daily oral dose - a margin of safety unparalleled by any pharmaceutical eye drop. In comparison, Restasis®
(the only approved drug for dry eye - an immune suppressant) and Vigamox®
(an antibiotic drug for eye infection) are used in a range of 1/400 - 1/800 of the oral dose.
This valuable discovery was not made by a pharmaceutical company, but by an independent researcher. The process of bringing such a discovery through the drug approval process is costly - up to $30 million in the USA alone, and can take up to 5 years.
Fortunately, since dipyridamole is a drug that is readily available, compounding pharmacies are permitted to prepare it. The concentration in eye drops is low enough to fall below the “drug” threshold and into “homeopathic” regulatory classification. This has enabled patients suffering from eye disorders to benefit from the dipyridamole eye drops discovery without losing precious time.
At the present time, research into dipyridamole eye drops is being conducted by Ariel University
in Israel and MedInsight Research Institute
- USA. Several hospitals / research departments plan to launch trials in the coming months. Concurrently, the process of commercialization and obtaining FDA (and similar international agencies) approval is being undertaken by RemedEye Inc., a U.S. company that owns the international intellectual property on the use of dipyridamole in eye drop form.
Make sure you do not miss any updates on development of this promising therapy by subscribing to our news list.